BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 17427221)

  • 1. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
    Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
    Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
    Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
    Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.
    Haneda H; Sasaki H; Lindeman N; Kawano O; Endo K; Suzuki E; Shimizu S; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Jpn J Clin Oncol; 2006 Feb; 36(2):69-75. PubMed ID: 16449241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
    Marchetti A; Martella C; Felicioni L; Barassi F; Salvatore S; Chella A; Camplese PP; Iarussi T; Mucilli F; Mezzetti A; Cuccurullo F; Sacco R; Buttitta F
    J Clin Oncol; 2005 Feb; 23(4):857-65. PubMed ID: 15681531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
    Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Noda K; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
    Am J Clin Pathol; 2007 Jul; 128(1):100-8. PubMed ID: 17580276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
    Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
    J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.
    Yoshida Y; Shibata T; Kokubu A; Tsuta K; Matsuno Y; Kanai Y; Asamura H; Tsuchiya R; Hirohashi S
    Lung Cancer; 2005 Oct; 50(1):1-8. PubMed ID: 15950315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
    Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
    Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type.
    Ninomiya H; Hiramatsu M; Inamura K; Nomura K; Okui M; Miyoshi T; Okumura S; Satoh Y; Nakagawa K; Nishio M; Horai T; Miyata S; Tsuchiya E; Fukayama M; Ishikawa Y
    Lung Cancer; 2009 Feb; 63(2):235-40. PubMed ID: 18571764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
    Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
    Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.
    McMillen E; Ye F; Li G; Wu Y; Yin G; Liu W
    Exp Lung Res; 2010 Nov; 36(9):531-7. PubMed ID: 20939760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
    Pan Q; Pao W; Ladanyi M
    J Mol Diagn; 2005 Aug; 7(3):396-403. PubMed ID: 16049312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.
    Mitsudomi T; Yatabe Y
    Cancer Sci; 2007 Dec; 98(12):1817-24. PubMed ID: 17888036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.